temozolomide has been researched along with Cancer of Intestines in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boutin, M | 3 |
| Mathews, A | 3 |
| Badesha, J | 3 |
| Paul, A | 3 |
| Safro, M | 3 |
| Gill, S | 3 |
| Stuart, HC | 3 |
| Schaeffer, D | 3 |
| Farnell, D | 3 |
| Loree, JM | 3 |
| Kesavan, M | 2 |
| Grover, P | 1 |
| Lam, WS | 1 |
| Claringbold, PG | 2 |
| Turner, JH | 2 |
| Thakral, P | 1 |
| Sen, I | 1 |
| Pant, V | 1 |
| Gupta, SK | 1 |
| Dureja, S | 1 |
| Kumari, J | 1 |
| Kumar, S | 1 |
| Un, P | 1 |
| Malasani, V | 1 |
| Costa, FP | 1 |
| Gumz, B | 1 |
| Pasche, B | 1 |
1 review available for temozolomide and Cancer of Intestines
| Article | Year |
|---|---|
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell | 2012 |
2 trials available for temozolomide and Cancer of Intestines
| Article | Year |
|---|---|
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; | 2021 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
2 other studies available for temozolomide and Cancer of Intestines
| Article | Year |
|---|---|
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabin | 2018 |